Caricamento azienda
Keep exploring
The themes Sanofi is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company1,36T USDA+
JNJJohnson & Johnson688,6B USDA+
MRKMerck & Co., Inc.364,3B USDA
NVSNovartis AG306,3B USDA
AMGNAmgen Inc.251,9B USDA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 ott 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 ott 2026CAGraded C, now A
Come guadagna
- Prescription medicines
- Vaccines
Compete con
Che cosa vende5
Dupixent
A biologic medicine used for several conditions; the call mentions its approval for chronic spontaneous urticaria in children.
ALTUVIIIO
A medicine for hemophilia A, a disorder that affects blood clotting.
AYVAKIT
A medicine used to treat systemic mastocytosis, a rare disease.
Mostra altri 2
Sarclisa
A medicine for multiple myeloma, a cancer of plasma cells.
Wayrilz
A medicine approved in Japan for immune thrombocytopenia, a condition involving low levels of platelets in the blood.
Chi lo compra3
- Patients receive Sanofi medicines through healthcare professionals who prescribe or administer them.
- People receive Sanofi vaccines through healthcare providers and public health programs.
- Pharmacies and clinics are involved in medicine access programs.
Su cosa si regge e cosa potrebbe romperlo
Da che cosa dipende l'attività
- 1Dupixent is developed with Regeneron under an alliance that Sanofi describes as strategically important.
- 2Vaccine sales vary with seasonal demand, including the timing and strength of influenza seasons.
- 3Sanofi depends on clinical studies to show that medicines in development work well enough to advance.
Che cosa potrebbe andare storto
- 1Sanofi says its global business exposes it to increased risks in specific areas.
- 2Clinical setbacks have included failed or discontinued studies involving Dupixent in lichen simplex chronicus, venglustat in Fabry disease, and other pipeline medicines.
- 3Sanofi and Regeneron have ongoing litigation over information sharing, while discussions about future collaboration continue without a reported agreement.
Informazioni su Sanofi
Sanofi makes prescription medicines and vaccines. Its medicines treat conditions including hemophilia A, systemic mastocytosis, and multiple myeloma. It also develops new medicines and vaccines through clinical trials.
- Sede
- Paris, France
- Fondata nel
- 1973 (founding year, high)
- Quotata su
- NYSE
- Chiusura dell'esercizio
- December 31
Costruito dai documenti depositati da Sanofi presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questa azienda rendiconta in EUR. Le cifre sono convertite in dollari a 1,00 USD = 0,904810 EUR, il tasso attuale, applicato allo stesso modo a tutti i periodi: così crescita e margini sono dell’azienda e non del cambio. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
